A5002626613- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Nuclear Structure and Function
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Extracellular vesicles in disease
- Kawasaki Disease and Coronary Complications
- Polyomavirus and related diseases
- Urinary Bladder and Prostate Research
- Advanced Drug Delivery Systems
- Clusterin in disease pathology
- Nanoparticle-Based Drug Delivery
- Transplantation: Methods and Outcomes
- Eosinophilic Disorders and Syndromes
- Cardiovascular Disease and Adiposity
- Immunodeficiency and Autoimmune Disorders
- Cardiovascular Effects of Exercise
Chinese Academy of Medical Sciences & Peking Union Medical College
2024-2025
Peking Union Medical College Hospital
2024-2025
Guangzhou University of Chinese Medicine
2021
Idiopathic multicentric Castleman disease (iMCD) is a rare characterized by polyclonal lymphoproliferation and systemic inflammation. Siltuximab, targeting interleukin-6 (IL-6), has been recommended as the first-line therapy for iMCD. However, substantial real-world data from China were still lacking, treatment patients with severe iMCD remained challenging. This single-center retrospective study investigated efficacy safety of siltuximab-based in 43 consecutive July 2022 to March 2024. The...
TAFRO syndrome, entailing thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly, was previously considered a subtype of idiopathic multicentric Castleman disease (iMCD-TAFRO), with the diagnosis requiring pathology supporting disease. However, lymph node biopsies may be difficult for patients (TAFRO without pathological evidence: TAFRO-w/op-iMCD), sometimes these do not confirm iMCD (TAFRO-w/o-iMCD). We aimed to compare clinical features prognosis subgroups. retrospectively...
Summary Idiopathic multicentric Castleman disease (iMCD) is a rare and heterogeneous lymphoproliferative disorder that lacks standardised treatment options for patients with refractory or relapsed (r/r) disease. Blocking Bruton's tyrosine kinase (BTK) has emerged as promising therapeutic approach iMCD without depleting B cells. This single‐centre, retrospective study enrolled 10 r/r who were treated orelabrutinib, novel, next‐generation BTK inhibitor. The median age at orelabrutinib...
Bronchiolitis obliterans (BO) is a rare and life-threatening complication of unicentric Castleman disease (UCD), which considered the leading cause death in UCD. However, few studies focused on characteristics UCD patients complicated with BO. This single-centre, retrospective study 281 diagnosed identified 18 (6.4%) UCD-BO had significantly lower age at diagnosis than without BO group. 94.4% deep lymph nodes involvement 83.3% them paraneoplastic pemphigus, were both higher Median forced...